| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454021 | Lung Cancer | 2018 | 6 Pages |
Abstract
The combination of amrubicin/carboplatin was an active first-line treatment for extensive stage SCLC, but showed no indication of increased efficacy compared to standard treatments. Severe myelosuppression was common with this regimen, in spite of prophylactic pegfilgrastim. These results are consistent with those of other trials in showing no role for amrubicin in the first-line treatment of SCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
David R. Spigel, John D. Hainsworth, Dianna L. Shipley, Tarek M. Mekhail, John D. Zubkus, David M. Waterhouse, Davey B. Daniel, Howard A. III, F. Anthony Greco,